One of the most significant achievements of recombinant DNA technology is the production of human insulin, which replaced the use of animal-derived (bovine or porcine) insulin in the 1980s. Before rDNA technology, insulin was extracted from the pancreases of slaughtered livestock, which often caused allergic reactions in patients due to slight amino acid differences. Recombinant human insulin is identical to the insulin produced by the human body, providing a safer and more consistent therapeutic option.

Beyond insulin, rDNA technology is used to produce a wide array of human hormones and growth factors, including Human Growth Hormone (hGH) for the treatment of growth disorders and Erythropoietin (EPO) for treating anemia. The Recombinant DNA Technology Market reports provide a comprehensive analysis of the clinical validation and regulatory pathways for these recombinant biologics. These products are synthesized in massive bioreactors, where controlled environments ensure that every batch meets stringent quality and potency standards.

The technology has also enabled the creation of "analogs"—modified versions of natural hormones that have improved properties. For example, fast-acting or long-acting insulin analogs are created by subtly changing the DNA sequence to alter how the protein hexamers dissociate after injection. This level of molecular tailoring allows clinicians to provide more personalized and effective treatments for patients with endocrine and metabolic disorders.